Growth Disorder Clinical Trial
Official title:
A Double-Blind, Randomized, Placebo-Controlled Clinical Trial of Luteinizing Hormone-Releasing Hormone Analog (LHRHa) in Pubertal Patients With Extreme Short Stature
Children with extreme short stature (height) and their families often experience significant
psychological stress related to concerns about adult height. In addition, short stature
often results in life-long emotional, social, and physical obstacles to the affected person.
Normal growth occurs in two phases. The first phase, known as childhood growth, occurs below
the age of 10. The second phase of growth, teen-age or adolescent growth, begins between the
ages of 10 and 15. In addition, puberty marks the time when the bone's growth plates
(epiphysis) begin to close, initiating the completion of linear growth (height).
Some children suffer from a condition called precocious puberty, meaning that puberty begins
at a younger age than normal. The development of medications known as synthetic LHRH analogs
have provided a method to delay puberty and treat these patients.
LHRHa (deslorelin) is a hormone created to act like naturally occurring LHRH. It been used
in patient's diagnosed with precocious (early onset) puberty. The drugs were able to regress
patient's clinical signs of puberty, decrease the levels of adult sex hormones produced, and
slow the rate of bone aging.
Children with extreme short stature and their families frequently experience significant
psychological stress related to concerns about adult height. Additionally, extreme short
stature often presents life-long emotional, social, and physical obstacles to the affected
individual. The onset of puberty in such patients presents a critical management problem
because puberty initiates the process of epiphyseal closure that terminates linear growth.
Until recently, there was no way to delay the onset of puberty in such patients. The
development of synthetic LHRH analogs, however, has provided such a method. Administration
of such analogs to children with precocious puberty caused a regression of their clinical
signs of puberty, a decrease in their gonadotropins and sex steroids, and a slowing of the
rate of bone age advancement.
We propose to treat pubertal children with extreme short stature with a long-acting analog
of luteinizing hormone-releasing hormone (D-Trp6-Pro9-NEt-LHRHa). The goal of LHRHa
treatment in these children is to halt the normal progression into puberty and thereby delay
epiphyseal fusion. We postulate that delay of puberty will prolong pre-pubertal growth prior
to the pubertal spurt and subsequent epiphyseal fusion, and thus will enhance ultimate
height. This study will test this hypothesis through a double-blind, randomized comparison
of the effect of LHRHa and placebo on final adult height. Patients will be treated with
LHRHa or placebo for 4 years, and will then be followed until they have completed puberty
and have stopped growing.
;
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01943084 -
A Trial to Investigate the Bioequivalence of Norditropin® (Somatropin) Versus Genotropin® (Somatropin) in Healthy Adult Subjects
|
Phase 1 | |
Completed |
NCT02580032 -
Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)
|
||
Completed |
NCT01578135 -
French National Registry of Children Born Small for Gestational Age Treated With Somatropin
|
||
Completed |
NCT01401244 -
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
|
Phase 1 | |
Recruiting |
NCT02769975 -
Evaluation of Children With Endocrine and Metabolic-Related Conditions
|
||
Completed |
NCT01778023 -
Efficacy and Safety of Recombinant Human Growth Hormone on Height Velocity in Subjects With Idiopathic Short Stature
|
Phase 3 | |
Completed |
NCT01543867 -
Safety and Efficacy of Long-term Somatropin Treatment in Children
|
N/A | |
Completed |
NCT00191074 -
Amendment (g) Unblinded Extension Phase of Somatropin in Patients With Idiopathic Short Stature
|
Phase 3 | |
Terminated |
NCT02311322 -
Genetic Causes of Growth Disorders
|
||
Withdrawn |
NCT01512095 -
Bioequivalence of Two Products (Norditropin® Versus Nutropin AQ®) in Healthy Adult Volunteers
|
Phase 1 | |
Completed |
NCT00262249 -
Effect of Growth Hormone in Children With Growth Hormone Deficiency
|
Phase 3 | |
Completed |
NCT02428296 -
Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation
|
Phase 2 | |
Completed |
NCT00174421 -
Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height
|
Phase 3 |